Platinum Compound

Search with Google Search with Bing

Information
Drug Name
Platinum Compound
Description
Entry(CIViC)
12
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
ovarian carcinoma BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 3 24240112 Detail
ovarian carcinoma BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 3 24240112 Detail
ovarian carcinoma BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Somatic 3 24240112 Detail
ovarian carcinoma BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Somatic 3 24240112 Detail
ovarian serous carcinoma AURKA OVEREXPRESSION
( ENST00000395913.7 ) AURKA OVEREXPRESSION
( ENST00000395913.7 )
B Predictive Supports Resistance N/A 3 27209210 Detail
bladder carcinoma ERBB2 MUTATION ERBB2 MUTATION C Predictive Supports Sensitivity/Response Somatic 3 25636205 Detail
pancreatic cancer BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION B Predictive Supports Sensitivity/Response Rare Germline 4 25072261 Detail
ovarian cancer ASS1 LOSS ASS1 LOSS D Predictive Supports Resistance Somatic 3 19533750 Detail
head and neck squamous cell carcinoma EGFR AMPLIFICATION
( ENST00000275493.7 ) EGFR AMPLIFICATION
( ENST00000275493.7 )
B Predictive Does Not Support Sensitivity/Response Somatic 4 21048039 Detail
lung non-small cell carcinoma WEE1 c.1141+1133A>G
( ENST00000299613.10, ENST00000450114.7, ENST00000681684.1 ) WEE1 c.1141+1133A>G
( ENST00000450114.7, ENST00000681684.1, ENST00000299613.10 )
B Predictive Supports Sensitivity/Response Common Germline 3 26057002 Detail
lung non-small cell carcinoma BIRC5 EXPRESSION BIRC5 NUCLEAR EXPRESSION B Predictive Supports Sensitivity/Response N/A 3 24961465 Detail
ovarian cancer BRCA1 UNDEREXPRESSION
( ENST00000357654.9 ) BRCA1 UNDEREXPRESSION
( ENST00000357654.9 )
B Predictive Supports Sensitivity/Response Somatic 3 21920589 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
In a study of ovarian carcinomas, 81% of tumors wi... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In a study of ovarian carcinomas, 81% of tumors wi... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In a study of ovarian carcinomas, 87% of tumors wi... BRCA1 BRCA1 LOSS-OF-FUNCTION BRCA1 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In a study of ovarian carcinomas, 87% of tumors wi... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
A study of 41 patients with high-grade ovarian ser... AURKA AURKA OVEREXPRESSION
( ENST00000395913.7 ) AURKA OVEREXPRESSION
( ENST00000395913.7 )
Resitance or Non-Reponse true CIViC Evidence detail
In patients with muscle-invasive bladder chancer, ... ERBB2 ERBB2 MUTATION ERBB2 MUTATION Sensitivity true CIViC Evidence detail
Patients with BRCA1/2 associated pancreatic adenoc... BRCA2 BRCA2 LOSS-OF-FUNCTION BRCA2 LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
Preclinical evidence for epigenetic inactivation o... ASS1 ASS1 LOSS ASS1 LOSS Resitance or Non-Reponse true CIViC Evidence detail
EGFR amplification was not a predictor of response... EGFR EGFR AMPLIFICATION
( ENST00000275493.7 ) EGFR AMPLIFICATION
( ENST00000275493.7 )
Sensitivity false CIViC Evidence detail
The presence of the WEE1 polymorphism rs3910384 co... WEE1 WEE1 c.1141+1133A>G
( ENST00000299613.10, ENST00000450114.7, ENST00000681684.1 ) WEE1 c.1141+1133A>G
( ENST00000450114.7, ENST00000681684.1, ENST00000299613.10 )
Sensitivity true CIViC Evidence detail
Patients with nuclear survivin (BIRC5) expression ... BIRC5 BIRC5 EXPRESSION BIRC5 NUCLEAR EXPRESSION Sensitivity true CIViC Evidence detail
Absent/low expression of BRCA1 (IHC) was associate... BRCA1 BRCA1 UNDEREXPRESSION
( ENST00000357654.9 ) BRCA1 UNDEREXPRESSION
( ENST00000357654.9 )
Sensitivity true CIViC Evidence detail